Cytoreductive  	Cytoreductive  	 NNP	B-NP
Surgery  	Surgery  	 NNP	I-NP
and  	and  	 CC	O
Hyperthermic  	Hyperthermic  	 NNP	B-NP
Intraperitoneal  	Intraperitoneal  	 NNP	I-NP
Chemotherapy  	Chemotherapy  	 NNP	I-NP
for  	for  	 IN	I-NP
Peritoneal  	Peritoneal  	 NNP	I-NP
Dissemination  	Dissemination  	 NNP	I-NP
from  	from  	 IN	O
Small  	Small  	 NNP	O
Bowel  	Bowel  	 NNP	B-NP
Malignancy 	Malignancy 	 NNP	I-NP
:  	:  	 :	O
Results  	Results  	 NNS	O
from  	from  	 IN	O
a  	a  	 DT	O
Single  	Single  	 NNP	O
Specialized  	Specialized  	 NNP	B-NP
Center  	Center  	 NNP	I-NP
Peritoneal  	Peritoneal  	 NNP	I-NP
dissemination  	dissemination  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
frequent  	frequent  	 JJ	O
pattern  	pattern  	 NN	O
of  	of  	 IN	O
recurrence  	recurrence  	 NN	O
and  	and  	 CC	O
metastasis  	metastasis  	 NN	B-NP
of  	of  	 IN	O
small  	small  	 JJ	B-NP
bowel  	bowel  	 JJ	I-NP
malignancy  	malignancy  	 NN	I-NP
( 	( 	 -LRB-	O
SBM 	SBM 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
survival  	survival  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
peritoneal  	peritoneal  	 JJ	B-NP
dissemination  	dissemination  	 NN	I-NP
from  	from  	 IN	O
SBM  	SBM  	 NNP	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
clear 	clear 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
there  	there  	 EX	O
is  	is  	 VBZ	O
no  	no  	 DT	O
consensus  	consensus  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
it 	it 	 PRP	O
.  	.  	 .	O
A  	A  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
31  	31  	 CD	O
selected  	selected  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
peritoneal  	peritoneal  	 JJ	B-NP
dissemination  	dissemination  	 NN	I-NP
from  	from  	 IN	O
SBM  	SBM  	 NNP	B-NP
were  	were  	 VBD	O
treated  	treated  	 VBN	O
by  	by  	 IN	O
cytoreductive  	cytoreductive  	 JJ	B-NP
surgery  	surgery  	 NN	I-NP
( 	( 	 -LRB-	O
CRS 	CRS 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
hyperthermic  	hyperthermic  	 FW	B-NP
intraperitoneal  	intraperitoneal  	 FW	I-NP
chemotherapy  	chemotherapy  	 FW	I-NP
( 	( 	 -LRB-	O
HIPEC 	HIPEC 	 NNP	B-NP
)  	)  	 -RRB-	O
between  	between  	 IN	O
January  	January  	 NNP	O
2006  	2006  	 CD	O
and  	and  	 CC	O
January  	January  	 NNP	O
2014 	2014 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
major  	major  	 JJ	O
focus  	focus  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
overall  	overall  	 JJ	O
survival 	survival 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
morbidity  	morbidity  	 NN	O
and  	and  	 CC	O
mortality 	mortality 	 NN	O
.  	.  	 .	O
Twenty-five  	Twenty-five  	 CD	O
patients  	patients  	 NNS	O
had  	had  	 VBD	O
small  	small  	 JJ	B-NP
bowel  	bowel  	 NN	I-NP
adenocarcinoma  	adenocarcinoma  	 NNS	I-NP
( 	( 	 -LRB-	O
SBA 	SBA 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
six  	six  	 CD	O
patients  	patients  	 NNS	O
had  	had  	 VBD	O
non-adenocarcinoma  	non-adenocarcinoma  	 NNP	B-NP
SBM 	SBM 	 NNP	I-NP
.  	.  	 .	O
HIPEC  	HIPEC  	 NNP	B-NP
was  	was  	 VBD	O
performed  	performed  	 VBN	O
on  	on  	 IN	O
21  	21  	 CD	O
patients 	patients 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
21  	21  	 CD	O
patients  	patients  	 NNS	O
received  	received  	 VBD	O
complete  	complete  	 JJ	O
cytoreduction 	cytoreduction 	 NN	B-NP
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
treatment-related  	treatment-related  	 JJ	O
mortality 	mortality 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
eight  	eight  	 CD	O
( 	( 	 -LRB-	O
25.8  	25.8  	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
had  	had  	 VBD	O
grade  	grade  	 CD	O
3-4  	3-4  	 CD	O
complications 	complications 	 NNS	O
.  	.  	 .	O
Until  	Until  	 IN	O
the  	the  	 DT	O
latest  	latest  	 JJS	O
follow-up 	follow-up 	 JJ	O
,  	,  	 ,	O
the  	the  	 DT	O
median  	median  	 JJ	B-NP
survival  	survival  	 NN	I-NP
of  	of  	 IN	O
31  	31  	 CD	O
patients  	patients  	 NNS	O
after  	after  	 IN	O
CRS  	CRS  	 NNP	B-NP
and  	and  	 CC	O
HIPEC  	HIPEC  	 NNP	B-NP
was  	was  	 VBD	O
36 months  	36 months  	 CD	O
( 	( 	 -LRB-	O
range  	range  	 NN	O
5-95 months 	5-95 months 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
median  	median  	 JJ	B-NP
survival  	survival  	 NN	I-NP
after  	after  	 IN	O
diagnosis  	diagnosis  	 NN	O
was  	was  	 VBD	O
51 months  	51 months  	 CD	O
( 	( 	 -LRB-	O
range  	range  	 NN	O
18-101 months 	18-101 months 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
For  	For  	 IN	O
25  	25  	 CD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
peritoneal  	peritoneal  	 JJ	B-NP
carcinomatosis  	carcinomatosis  	 NN	I-NP
from  	from  	 IN	O
SBA 	SBA 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
median  	median  	 JJ	B-NP
survival  	survival  	 NN	I-NP
after  	after  	 IN	O
CRS  	CRS  	 NNP	B-NP
and  	and  	 CC	O
HIPEC  	HIPEC  	 NNP	B-NP
was  	was  	 VBD	O
36 months  	36 months  	 CD	O
( 	( 	 -LRB-	O
range  	range  	 NN	O
6-95 months 	6-95 months 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
median  	median  	 JJ	B-NP
survival  	survival  	 NN	I-NP
after  	after  	 IN	O
diagnosis  	diagnosis  	 NN	O
was  	was  	 VBD	O
50 months  	50 months  	 CD	O
( 	( 	 -LRB-	O
range  	range  	 NN	O
18-101 months 	18-101 months 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Multivariate  	Multivariate  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
revealed  	revealed  	 VBD	O
that  	that  	 DT	O
peritoneal  	peritoneal  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
index  	index  	 NN	I-NP
< 	< 	 SYM	O
15  	15  	 CD	O
( 	( 	 -LRB-	O
p = 0.009 	p = 0.009 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
HIPEC  	HIPEC  	 NNP	B-NP
( 	( 	 -LRB-	O
p   	p   	 NNP	O
< 	< 	 SYM	O
 0.001 	 0.001 	 NNP	O
)  	)  	 -RRB-	O
were  	were  	 VBD	O
independent  	independent  	 JJ	O
predictors  	predictors  	 NN	O
of  	of  	 IN	O
better  	better  	 JJR	O
survival  	survival  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
peritoneal  	peritoneal  	 JJ	B-NP
dissemination  	dissemination  	 NN	I-NP
from  	from  	 IN	O
SBM  	SBM  	 NNP	B-NP
treated  	treated  	 VBD	O
by  	by  	 IN	O
CRS  	CRS  	 NNP	B-NP
and  	and  	 CC	O
HIPEC 	HIPEC 	 NNP	B-NP
.  	.  	 .	O
Until  	Until  	 IN	O
more  	more  	 JJR	O
data  	data  	 NNS	O
become  	become  	 VBP	O
available 	available 	 JJ	O
,  	,  	 ,	O
a  	a  	 DT	O
reasonable  	reasonable  	 JJ	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
SBM  	SBM  	 NNP	B-NP
is  	is  	 VBZ	O
CRS  	CRS  	 NNP	B-NP
and  	and  	 CC	O
HIPEC 	HIPEC 	 NNP	B-NP
.  	.  	 .	O
It  	It  	 PRP	O
can  	can  	 MD	O
be  	be  	 VB	O
applied  	applied  	 VBN	O
with  	with  	 IN	O
acceptable  	acceptable  	 JJ	O
safety  	safety  	 NN	O
in  	in  	 IN	O
selected  	selected  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
peritoneal  	peritoneal  	 JJ	B-NP
dissemination  	dissemination  	 NN	I-NP
from  	from  	 IN	O
SBM 	SBM 	 NNP	B-NP
.  	.  	 .	O
